CODX stock news · Co-Diagnostics, Inc.
Get alerts for CODX
Follow Co-Diagnostics, Inc. (CODX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CODXCo-Diagnostics, Inc. has signed a big loan deal with J.J. Astor & Co. for up to $3.1 million.
Bad for CODXCo-Diagnostics received about $2.0 million for working cash and can repay early without penalty. But the costly loan terms and possible added shares weigh against the company.
Co-Diagnostics, Inc. has signed a big loan deal worth $2.1 million with J.J. Astor & Co.
Bad for CODXCo-Diagnostics got about $2 million in loan cash, but repayment terms and possible share conversions burden the company and may shrink owners’ slice.
Co-Diagnostics, Inc. says it will hold a meeting for investors and analysts on September 16, 2026.
NeutralCo-Diagnostics filed an 8-K to furnish an investor presentation on its ReadyGo collaboration and India plans; the disclosure is neutral for CODX.
Co-Diagnostics, Inc. says it is teaming up with ReadyGo Diagnostics Ltd.
NeutralCo-Diagnostics issued an 8-K about a collaboration with ReadyGo; without deal terms or financials, this press release does not change the company's outlook.
Keep an eye on United Natural Foods, ABM Industries, and 3 other stocks as Tuesday approaches.
NeutralCo-Diagnostics announced its CFO left and named a principal financial officer, and the stock had a small after-hours rise, which is neither clearly positive nor negative for the company overall.
Keep an eye on United Natural Foods, ABM Industries, and 3 other stocks this Tuesday.
NeutralCo-Diagnostics announced its CFO left and named a replacement, while shares rose a little after hours; that personnel change and small move do not clearly change the company's prospects.
Q2 2026 financial results delivered by Co-Diagnostics: Complete earnings call transcript available.
Good for CODXCo-Diagnostics' Q2 2026 earnings report shows a slight increase in revenue and a significant decrease in operating expenses, which may enhance investor confidence. The company's progress in regulatory submissions for new assays and expansion of its platform capabilities are key developments that could drive future growth.